Vision Grants

The Vision Grant Award Program is a research funding initiative jointly managed by the Preeclampsia Foundation and Preeclampsia Foundation Canada. The program seeks to catalyze impactful, early-stage research into preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy. It is open to post-doctoral researchers, Clinical Fellows, and Early Stage Investigators, with the goal of supporting novel, potentially transformative research that could significantly influence clinical practices and improve outcomes for mothers and infants affected by these conditions. The Preeclampsia Foundation, founded in 2000 as a U.S.-based 501(c)(3) nonprofit, is committed to improving the health outcomes of hypertensive pregnancy disorders through community engagement, education, healthcare practice improvement, and research acceleration. Its Canadian counterpart, Preeclampsia Foundation Canada, operates with a similar mission under the Canada Not-for-profit Corporations Act and has invested significantly in research since 2016. Together, the two foundations have funded over three-quarters of a million dollars in pioneering studies that have not only advanced science but also garnered broader funding and professional attention. Funders of the Vision Grant Awards include the foundations themselves, the Doane Grant Thornton Foundation, and the Cara HELLPs research fund. There are three specific Vision Grant awards for 2026. The Preeclampsia Foundation Vision Grant offers up to $20,000 USD and is focused on addressing health inequities in the United States. Eligible projects must include components such as participant enrollment in The Preeclampsia Registry (TPR) or usage of its data. International applicants are welcome to apply. The Maya B. Dash Vision Grant, funded by the Doane Grant Thornton Foundation, offers up to $20,000 CAD and is exclusively for Canadian investigators focusing on health disparities affecting Black Canadian populations. The Cara HELLPs Vision Grant, offering up to $25,000 CAD, supports international research specifically targeting HELLP syndrome. Applications must be submitted via ProposalCentral by 11:59 PM (Eastern Time) on May 27, 2026. The submission process includes several required components: a research plan (up to six pages), budget documentation (excluding PI salary, travel, and indirect costs), institutional assurances, and letters of support. Applications must also include a lay letter to a patient or their family that describes the project in accessible terms. Investigators must register for an ORCID ID and include it in their application materials. International applications are accepted, but all submissions must be in English. The online submission platform allows applicants to save and return to proposals, and permits “unsubmitting” prior to the deadline to make final edits. All applicants are encouraged to consult the eligibility checker and review formatting guidance available through ProposalCentral. While indirect costs are not covered, budget lines may include IRB fees, personnel (excluding PI salary), and Registry data access fees. Applications proposing data collection through TPR must consider service or development fees, depending on the data level required. The evaluation process prioritizes projects with the potential to influence clinical management and improve outcomes. A mentor is required for post-doctoral and clinical fellows, while Early Stage Investigators must include a letter of support from their department head. The funders aim to support investigators in early research career stages and expect funded research to fill knowledge gaps and create pathways to broader funding and clinical impact.

Ensure research aligns with specific award priorities (e.g., HELLP focus or health equity). Non-aligned projects will be rejected.